Select Publications
Book Chapters
2019, 'HIV Infection as a Model of Accelerated Immunosenescence', in Handbook of Immunosenescence, Springer International Publishing, pp. 1961 - 1989, http://dx.doi.org/10.1007/978-3-319-99375-1_50
,2018, 'Mechanisms for Controlling HIV-1 infection: a Gene Therapy Approach', in In Vivo and Ex Vivo Gene Therapy for Inherited and Non-Inherited Disorders, http://dx.doi.org/10.5772/intechopen.72962
,2017, 'HIV Infection as a Model of Accelerated Immunosenescence.', in Bachtarzi H (ed.), Handbook of Immunosenescence Basic Understanding and Clinical Implications, http://dx.doi.org/10.1007/978-3-319-64597-1_50-1
,2014, 'AIDS : Clinical Manifestations', in Encyclopaedia of Life Sciences, John Wiley & Sons, http://dx.doi.org/10.1002/9780470015902.a0002237.pub3
,2013, 'The Immunocompromised Patient', in Fulde G; Fulde S (ed.), Emergency Medicine: the Principles of Practice, Churchill Livingston, Sydney, pp. 862 - 889, https://www.elsevier.com/books/emergency-medicine/fulde/978-0-7295-8146-2
,2012, 'Chapter 6 Acute HIV infection', in Sande's HIV/AIDS Medicine, Elsevier, pp. 77 - 88, http://dx.doi.org/10.1016/b978-1-4557-0695-2.00006-7
,2009, 'Immune Restoration Diseases', in Hoy J; Lewin S; Post JJ; Street A (ed.), HIV Management in Australasia: a guide for clinical care, pp. 287 - 294
,2009, 'The immunosuppressed patient', in Fulde G (ed.), Emergency Medicine, the Principles of Practice, Elsevier, Australia, pp. 665 - 686, http://shop.mja.com.au/
,2009, 'The immunosuppressed patient', in Emergency Medicine, Elsevier, pp. 665 - 686, http://dx.doi.org/10.1016/b978-0-7295-3876-3.10042-5
,2008, 'Acute HIV Infection', in Volberding PA; Sande MA; Greene WC; Lange JMA (ed.), Global HIV/AIDS Medicine, Elsevier Inc, Philadelphia, PA, pp. 63 - 74
,2008, 'CHAPTER 6 Acute HIV Infection', in Global HIV/AIDS Medicine, Elsevier, pp. 63 - 74, http://dx.doi.org/10.1016/b978-1-4160-2882-6.50010-1
,2008, 'Infeccion primaria por HIV. [Primary HIV-1 Infection]', in Benettuci JA (ed.), SIDA y Enfermedades Associadas (AIDS and Infectious Diseases), 3a edicion., FUNDAI, Buenos Aires, pp. 155 - 170
,2007, 'Acute HIV Infection', in Global HIV/AIDS Medicine, pp. 63 - 74, http://dx.doi.org/10.1016/B978-1-4160-2882-6.50010-1
,2005, 'Therapeutic vaccination in PHI', in Jenssen H; Jager H (ed.), Primary HIV Infection ? Pathology, Diagnosis, Management, Thieme, Stuttgart, pp. 48 - 63
,1997, 'Early HIV-induced immune depletion', in Stewart GJ (ed.), Managing HIV, Medical Journal of Australia
,1997, 'Strategies in managing HIV', in Stewart GJ (ed.), Managing HIV
,Journal articles
2024, 'Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection.', Nat Commun, 15, pp. 3315, http://dx.doi.org/10.1038/s41467-024-47720-8
,2024, 'Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials', Journal of Infectious Diseases, 229, pp. 1229 - 1238, http://dx.doi.org/10.1093/infdis/jiad425
,2024, 'Advances in HIV Gene Therapy', International Journal of Molecular Sciences, 25, http://dx.doi.org/10.3390/ijms25052771
,2024, 'Molecular epidemiology to aid virtual elimination of HIV transmission in Australia', Virus Research, 341, http://dx.doi.org/10.1016/j.virusres.2024.199310
,2024, 'Novel clinical applications of functional assays to measure antigen-specific cellular immunity', Pathology, 56, pp. S27 - S27, http://dx.doi.org/10.1016/j.pathol.2023.12.101
,2023, 'Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients', Nature Communications, 14, http://dx.doi.org/10.1038/s41467-023-36295-5
,2023, 'Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia', PLoS ONE, 18, http://dx.doi.org/10.1371/journal.pone.0289907
,2023, 'Delabeling, safety, and impact of β-lactam allergy testing: A systematic review', Journal of Allergy and Clinical Immunology: Global, 2, http://dx.doi.org/10.1016/j.jacig.2023.100160
,2023, 'Agreements, Behaviour, and Change: Sex Outside the Relationship in Male HIV-negative Partners in HIV Serodiscordant Relationships in Australia, Brazil, and Thailand', AIDS and Behavior, 27, pp. 3098 - 3108, http://dx.doi.org/10.1007/s10461-023-04030-2
,2023, 'Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial', The Lancet Respiratory Medicine, 11, pp. 791 - 803, http://dx.doi.org/10.1016/S2213-2600(23)00147-9
,2023, 'Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2', Antiviral Research, 217, http://dx.doi.org/10.1016/j.antiviral.2023.105677
,2023, 'The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC', Annals of Clinical and Translational Neurology, 10, pp. 1338 - 1352, http://dx.doi.org/10.1002/acn3.51825
,2023, 'Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial', The Lancet Infectious Diseases, 23, pp. 847 - 855, http://dx.doi.org/10.1016/S1473-3099(23)00067-1
,2023, 'T follicular helper cell responses to SARS-CoV-2 vaccination among healthy and immunocompromised adults', Immunology and Cell Biology, 101, pp. 504 - 513, http://dx.doi.org/10.1111/imcb.12635
,2023, 'The crossroads: divergent roles of virus-specific CD4+ T lymphocytes in determining the outcome for human papillomavirus infection', Immunology and Cell Biology, 101, pp. 525 - 534, http://dx.doi.org/10.1111/imcb.12650
,2023, 'Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level', eBioMedicine, 90, http://dx.doi.org/10.1016/j.ebiom.2023.104545
,2023, 'Viral competition assay to assess the role of HIV-1 proteins in immune evasion', STAR Protocols, 4, http://dx.doi.org/10.1016/j.xpro.2022.102025
,2023, 'Parallel analysis of multiple human memory CD4+ T-cell subsets within antigen-specific responses using cell proliferation dyes', Immunology and Cell Biology, 101, pp. 171 - 178, http://dx.doi.org/10.1111/imcb.12606
,2023, 'Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses', American Journal of Hematology, 98, pp. 131 - 139, http://dx.doi.org/10.1002/ajh.26619
,2023, 'Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19', Clinical Immunology, 246, http://dx.doi.org/10.1016/j.clim.2022.109209
,2023, 'Immune response to COVID‐19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy', eJHaem, 4, pp. 728 - 732, http://dx.doi.org/10.1002/jha2.724
,2023, 'Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.', NEJM Evid, 2, http://dx.doi.org/10.1056/evidoa2200302
,2022, 'High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1032911
,2022, 'Phenotypic and functional characteristics of highly differentiated CD57+NKG2C+NK cells in HIV-1-infected individuals', Clinical and Experimental Immunology, 210, pp. 163 - 174, http://dx.doi.org/10.1093/cei/uxac082
,2022, 'SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern', eBioMedicine, 84, http://dx.doi.org/10.1016/j.ebiom.2022.104270
,2022, 'Frontline workers: Mediators of mucosal immunity in community acquired pneumonia and COVID-19', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.983550
,2022, 'Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 A Randomized Controlled Trial', Annals of Internal Medicine, 175, pp. 1266 - 1274, http://dx.doi.org/10.7326/M22-1503
,2022, 'Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT', HIV Research & Clinical Practice, 23, pp. 37 - 46, http://dx.doi.org/10.1080/25787489.2022.2103572
,2022, 'Standardized testing and written communication improve patient understanding of beta-lactam allergy testing outcomes: A multicenter, prospective study', Journal of Allergy and Clinical Immunology: Global, 1, pp. 99 - 105, http://dx.doi.org/10.1016/j.jacig.2022.05.003
,2022, 'Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection', Pharmaceutics, 14, http://dx.doi.org/10.3390/pharmaceutics14071352
,2022, 'PB2087: EFFICACY OF A 3RD COVID VACCINE, INCLUDING DURING A BTKI PAUSE, IN INDIVIDUALS WITH WALDENSTRÖM MACROGLOBULINEMIA AND FOLLICULAR LYMPHOMA', HemaSphere, 6, pp. 1958 - 1959, http://dx.doi.org/10.1097/01.hs9.0000851180.32970.18
,2022, 'Navigating the complexity of chronic HIV-1 associated immune dysregulation', Current Opinion in Immunology, 76, http://dx.doi.org/10.1016/j.coi.2022.102186
,2022, 'Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia', Nature Microbiology, 7, pp. 896 - 908, http://dx.doi.org/10.1038/s41564-022-01135-7
,2022, 'Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial', The Lancet Infectious Diseases, 22, pp. 622 - 635, http://dx.doi.org/10.1016/S1473-3099(21)00751-9
,